Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
作者： Michael Amatangelo , Azat Garipov , Hua Li , Jose R. Conejo-Garcia , David Speicher
DOI: 10.4161/CC.25163
关键词: Tumor microenvironment 、 Enzyme 、 Methyltransferase 、 EZH2 、 B-cell lymphoma 、 Cell culture 、 Matrigel 、 Cancer research 、 Apoptosis 、 Biology
摘要: Inhibitors of EZH2 methyltransferase activity have been demonstrated to selectively suppress the growth diffused large B cell lymphoma (DLBCL) cells with gain-of-function mutations in EZH2, while exhibiting very limited effects on DLBCL wild-type EZH2. Given that is often overexpressed but not mutated solid tumors, it important investigate determinants sensitivity tumor inhibitors. In current study, we show three-dimensional (3D) culture epithelial ovarian cancer (EOC) overexpress sensitizes these inhibition. Treatment EOC GSK343, a specific inhibitor methyltransferase, decreases level H3K27Me3, product EZH2’s enzymatic activity. However, GSK343 exhibited conventional two-dimensional (2D) culture. contrast, significantly suppressed cultured 3D matrigel extrac...
landesbioscience.com参考文章(27)
Tim Child, Lawrence Impey, Obstetrics and Gynaecology ,(1999)
Thomas Jenuwein, The epigenetic magic of histone lysine methylation. FEBS Journal. ,vol. 273, pp. 3121- 3135 ,(2006) , 10.1111/J.1742-4658.2006.05343.X
Ie-Ming Shih, Robert J. Kurman, Ovarian Tumorigenesis : A Proposed Model Based on Morphological and Molecular Genetic Analysis American Journal of Pathology. ,vol. 164, pp. 1511- 1518 ,(2004) , 10.1016/S0002-9440(10)63708-X
Angelo Ferraro, Despoina Mourtzoukou, Vivian Kosmidou, Spiros Avlonitis, George Kontogeorgos, George Zografos, Alexander Pintzas, EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial–Mesenchymal Transition and anoikis in colon cancer cells The International Journal of Biochemistry & Cell Biology. ,vol. 45, pp. 243- 254 ,(2013) , 10.1016/J.BIOCEL.2012.10.009
Claudia Fischbach, Ruth Chen, Takuya Matsumoto, Tobias Schmelzle, Joan S Brugge, Peter J Polverini, David J Mooney, Engineering tumors with 3D scaffolds. Nature Methods. ,vol. 4, pp. 855- 860 ,(2007) , 10.1038/NMETH1085
Sharad K. Verma, Xinrong Tian, Louis V. LaFrance, Céline Duquenne, Dominic P. Suarez, Kenneth A. Newlander, Stuart P. Romeril, Joelle L. Burgess, Seth W. Grant, James A. Brackley, Alan P. Graves, Daryl A. Scherzer, Art Shu, Christine Thompson, Heidi M. Ott, Glenn S. Van Aller, Carl A. Machutta, Elsie Diaz, Yong Jiang, Neil W. Johnson, Steven D. Knight, Ryan G. Kruger, Michael T. McCabe, Dashyant Dhanak, Peter J. Tummino, Caretha L. Creasy, William H. Miller, Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Medicinal Chemistry Letters. ,vol. 3, pp. 1091- 1096 ,(2012) , 10.1021/ML3003346
Jayanta Debnath, Senthil K. Muthuswamy, Joan S. Brugge, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures Methods. ,vol. 30, pp. 256- 268 ,(2003) , 10.1016/S1046-2023(03)00032-X
Sooryanarayana Varambally, Saravana M. Dhanasekaran, Ming Zhou, Terrence R. Barrette, Chandan Kumar-Sinha, Martin G. Sanda, Debashis Ghosh, Kenneth J. Pienta, Richard G. A. B. Sewalt, Arie P. Otte, Mark A. Rubin, Arul M. Chinnaiyan, The polycomb group protein EZH2 is involved in progression of prostate cancer Nature. ,vol. 419, pp. 624- 629 ,(2002) , 10.1038/NATURE01075
Yong Jae Shin, Jeong-Ho Kim, The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells PLoS ONE. ,vol. 7, pp. e30393- ,(2012) , 10.1371/JOURNAL.PONE.0030393
Louis V. LaFrance, Mark Mellinger, Celine Duquenne, Xinrong Tian, Ryan G. Kruger, Charles F. McHugh, Martin Brandt, William H. Miller, Dashyant Dhanak, Sharad K. Verma, Peter J. Tummino, Caretha L. Creasy, Michael T. McCabe, Heidi M. Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S. Van Aller, Yan Liu, Alan P. Graves, Anthony Della Pietra III, Elsie Diaz, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. ,vol. 492, pp. 108- 112 ,(2012) , 10.1038/NATURE11606